Publications by authors named "A Harle"

Purpose: This study aims to identify a combination of clinical, demographic, and patient competence determinants of patients' communication with doctors and nurses in an international sample of cancer patients.

Methods: For our cross-sectional study, cancer patients assessed their communication with their doctors or nurses at the start of their treatment. Patients completed EORTC communication questionnaire QLQ-COMU26 to assess ten areas of communication with their doctor or nurses plus another item to assess how competent they felt when communicating with professionals.

View Article and Find Full Text PDF
Article Synopsis
  • - The EORTC QLQ-COMU26 is a newly developed questionnaire aimed at assessing how cancer patients perceive their communication with healthcare professionals, tested for validity and reliability among a diverse international sample.
  • - In a study with 498 cancer patients across 10 European countries, Japan, Jordan, and India, the questionnaire demonstrated clarity and minimal emotional distress, with strong reliability and appropriate scale structure confirmed through various assessments.
  • - The QLQ-COMU26 effectively identified differences in patient experiences based on factors like sex, education, and satisfaction with communication, as well as captured changes over time related to patient interactions with healthcare providers.
View Article and Find Full Text PDF

Objective: Shared decision making is important when decisions are preference sensitive, as in incurable cancer. A prerequisite for shared decision making is health literacy, which is essential to facilitate good understanding of an individual's current situation, the decision to be made, and the options available to them. This study sought to learn about the challenges for shared decision making faced by patients with incurable cancer and health literacy difficulties.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Therapeutic options for PDAC are primarily restricted to surgery in the early stages of the disease or chemotherapy in advanced disease. Only a subset of patients with germline defects in BRCA1/2 genes can potentially benefit from personalized therapy, with the PARP inhibitor olaparib serving as a maintenance treatment for metastatic disease.

View Article and Find Full Text PDF